Akari Therapeutics Financials
| AKTX Stock | USD 1.12 0.02 1.75% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.947 |
|
|
Investors should never underestimate Akari Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Akari Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Akari Therapeutics PLC.
Net Income |
|
Akari | Select Account or Indicator |
Understanding current and past Akari Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Akari Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Akari Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Akari Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Akari Therapeutics PLC. Check Akari Therapeutics' Beneish M Score to see the likelihood of Akari Therapeutics' management manipulating its earnings.
Akari Therapeutics Stock Summary
Akari Therapeutics competes with Armata Pharmaceuticals, Anebulo Pharmaceuticals, Processa Pharmaceuticals, Salarius Pharmaceuticals, and Pulmatrix. Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Akari Therapeutics, Plc is based in London, the United Kingdom. Akari Therapeutics is traded on NASDAQ Exchange in the United States.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US00972G1085 |
| CUSIP | 00972G108 15119A202 00972G207 |
| Location | New York; U.S.A |
| Business Address | 22 Boston Wharf |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.akaritx.com |
| Phone | 929 274 7510 |
| Currency | USD - US Dollar |
Akari Therapeutics Key Financial Ratios
| Return On Equity | -12.81 | ||||
| EBITDA | (16.8 M) | ||||
| Net Income | (10.01 M) | ||||
| Cash Per Share | 0.14 X | ||||
| Debt To Equity | 0.07 % |
Akari Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 10.3M | 17.6M | 11.6M | 13.8M | 4.4M | 4.1M | |
| Other Current Liab | 4.2M | 1.8M | 4.3M | 11.1M | 2.9M | 5.7M | |
| Net Debt | (5.7M) | (14.1M) | (9.4M) | (13.2M) | (3.8M) | (4.0M) | |
| Retained Earnings | (138.2M) | (156.6M) | (199.7M) | (217.5M) | (227.5M) | (216.1M) | |
| Accounts Payable | 1.2M | 3.4M | 1.8M | 947K | 1.7M | 2.1M | |
| Cash | 5.7M | 14.1M | 9.4M | 13.2M | 3.8M | 3.7M | |
| Total Liab | 6.5M | 5.2M | 6.1M | 12.0M | 4.6M | 8.1M | |
| Total Current Assets | 10.3M | 17.6M | 11.6M | 13.8M | 4.3M | 4.1M | |
| Common Stock | 32.0M | 385K | 476.0K | 744.5K | 1.3M | 1.3M | |
| Intangible Assets | 30K | 27K | 22.9K | 16.9K | 14K | 13.3K | |
| Net Tangible Assets | 3.1M | (1.8M) | 9.4M | 5.5M | 5.0M | 4.7M | |
| Other Current Assets | 1.0M | 521.9K | 2.3M | 564.8K | 496K | 954.4K | |
| Net Invested Capital | (1.8M) | 9.4M | 5.6M | 1.8M | 1.6M | 1.5M | |
| Net Working Capital | (1.8M) | 9.4M | 5.5M | 1.8M | 1.6M | 1.5M | |
| Capital Stock | 32.0M | 384.7K | 476.0K | 744.5K | 670.0K | 636.5K |
Akari Therapeutics Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 267K | 205K | 210.1K | 5.3M | 6.1M | 6.4M | |
| Operating Income | (24.9M) | (18.0M) | (17.2M) | (23.1M) | (16.8M) | (17.6M) | |
| Ebit | (24.9M) | (20.5M) | (17.2M) | (23.1M) | (16.8M) | (17.6M) | |
| Research Development | 16.6M | 12.2M | 9.1M | 9.6M | 12.1M | 10.9M | |
| Ebitda | (25.0M) | (20.4M) | (17.2M) | (23.1M) | (16.8M) | (17.6M) | |
| Income Before Tax | (24.8M) | (20.5M) | (17.4M) | (17.7M) | (10.0M) | (10.5M) | |
| Net Income | (21.8M) | (17.6M) | (17.6M) | (7.0M) | (10.0M) | (10.5M) | |
| Income Tax Expense | (3.0M) | (2.9M) | 182.6K | (10.8M) | (9.7M) | (9.2M) | |
| Gross Profit | (19.2K) | (8.9K) | (4.1K) | (3.7K) | (4K) | (4.2K) | |
| Cost Of Revenue | 19.2K | 8.9K | 4.1K | 3.7K | 4K | 3.8K | |
| Interest Income | 5.5K | 13.6K | 10.6K | 45.9K | 41.3K | 39.3K | |
| Net Interest Income | 5.5K | 13.6K | 10.6K | 45.9K | 41.3K | 70.5K |
Akari Therapeutics Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Akari Therapeutics PLC. It measures of how well Akari is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Akari Therapeutics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Akari had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Akari Therapeutics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (236K) | 8.3M | (4.7M) | 3.9M | (9.4M) | (8.9M) | |
| Free Cash Flow | (12.3M) | (17.0M) | (18.8M) | (21.5M) | (16.4M) | (17.3M) | |
| Other Non Cash Items | 169K | 3.2M | 242.5K | (5.3M) | (7.6M) | (7.3M) | |
| Net Income | (24.8M) | (20.5M) | (17.4M) | (17.7M) | (10.0M) | (10.5M) | |
| End Period Cash Flow | 5.7M | 14.1M | 9.4M | 13.2M | 3.8M | 3.7M | |
| Change To Netincome | (1.7M) | 1.1M | 177.9K | 557.2K | 501.4K | 476.4K |
Akari Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Akari Therapeutics's current stock value. Our valuation model uses many indicators to compare Akari Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Akari Therapeutics competition to find correlations between indicators driving Akari Therapeutics's intrinsic value. More Info.Akari Therapeutics PLC is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Akari Therapeutics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Akari Therapeutics' earnings, one of the primary drivers of an investment's value.Akari Therapeutics PLC Systematic Risk
Akari Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Akari Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Akari Therapeutics PLC correlated with the market. If Beta is less than 0 Akari Therapeutics generally moves in the opposite direction as compared to the market. If Akari Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Akari Therapeutics PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Akari Therapeutics is generally in the same direction as the market. If Beta > 1 Akari Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Akari Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Akari Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Akari Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Akari Therapeutics November 29, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Akari Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Akari Therapeutics PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of Akari Therapeutics PLC based on widely used predictive technical indicators. In general, we focus on analyzing Akari Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Akari Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.24) | |||
| Maximum Drawdown | 47.27 | |||
| Value At Risk | (12.59) | |||
| Potential Upside | 6.04 |
Additional Tools for Akari Stock Analysis
When running Akari Therapeutics' price analysis, check to measure Akari Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Akari Therapeutics is operating at the current time. Most of Akari Therapeutics' value examination focuses on studying past and present price action to predict the probability of Akari Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Akari Therapeutics' price. Additionally, you may evaluate how the addition of Akari Therapeutics to your portfolios can decrease your overall portfolio volatility.